首页 > 最新文献

Acta Gastro-Enterologica Belgica最新文献

英文 中文
New drugs in chronic hepatitis B. 慢性乙型肝炎新药。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
Y Horsmans
{"title":"New drugs in chronic hepatitis B.","authors":"Y Horsmans","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"440-2"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic therapy of Barrett's oesophagus: critical review. 巴雷特食管的内镜治疗:综述。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
T De Ronde, J P Martinet, M Melange

Barrett's oesophagus is known as one of the most important risk factor of oesophageal adenocarcinoma. Because of the increasing incidence of these latter, many endoscopic methods such as argon plasma coagulation, photodynamic therapy or endoscopic mucosal resection are now in evaluation in order to eradicate Barrett's oesophagus or to treat dysplasia and early cancers arising from this metaplasia. The aim of this paper is to comment these techniques and discuss their usefulness.

Barrett食管被认为是食管腺癌最重要的危险因素之一。由于后者的发病率越来越高,目前正在评估许多内镜方法,如氩等离子凝固、光动力疗法或内镜粘膜切除术,以根除巴雷特食管或治疗由这种化生引起的发育不良和早期癌症。本文的目的是评论这些技术并讨论它们的用途。
{"title":"Endoscopic therapy of Barrett's oesophagus: critical review.","authors":"T De Ronde,&nbsp;J P Martinet,&nbsp;M Melange","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Barrett's oesophagus is known as one of the most important risk factor of oesophageal adenocarcinoma. Because of the increasing incidence of these latter, many endoscopic methods such as argon plasma coagulation, photodynamic therapy or endoscopic mucosal resection are now in evaluation in order to eradicate Barrett's oesophagus or to treat dysplasia and early cancers arising from this metaplasia. The aim of this paper is to comment these techniques and discuss their usefulness.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"390-2"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel nonsteroidal anti-inflammatory drugs. 新型非甾体抗炎药。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
Y Boutsen, W Esselinckx

The authors first briefly review how the concept of COX-2 selectivity was brought to light, then tested against the known gastrotoxicity ranking of currently used NSAIDs, from the old classics to the most recent. One truly selective COX-2 agent--celecoxib--is now being marketed in an ever increasing number of countries. So far it seems to keep its main promises, i.e. high--albeit not total--safety regarding gastrointestinal adverse effects, and undisturbed platelet function. Association with warfarin drugs seems to raise no problems, but one should still be wary of possible renal side-effects. Efficacy, at least as assessed in osteoarthritis and rheumatoid patients, appears satisfactory. However, treatment of intense inflammatory crises, such as gout or ankylosing spondylitis, has not been assessed, as yet. Another COX-2 agent--rofecoxib--is on the brink of being released. Its even more potent COX-2 selectivity raises new issues. What about some COX-1 activity that several authors detected in rheumatic synovitis? On the other hand, in particular circumstances, organs such as the stomach, the kidney and small blood vessels, seem to have their homeostasis partly controlled by COX-2 mechanisms also. These questions should be answered soon, whilst clinical experience with the COX-2 agent builds up.

作者首先简要回顾了COX-2选择性的概念是如何被揭示出来的,然后针对目前使用的非甾体抗炎药的已知胃毒性排名进行了测试,从旧的经典到最新的。一种真正具有选择性的COX-2药物——塞来昔布——现在正在越来越多的国家上市。到目前为止,它似乎保持了它的主要承诺,即对胃肠道不良反应的高安全性(尽管不是完全的)和不受干扰的血小板功能。与华法林药物联合使用似乎没有问题,但仍应警惕可能的肾脏副作用。至少在骨关节炎和类风湿患者中,疗效令人满意。然而,治疗强烈的炎症危机,如痛风或强直性脊柱炎,尚未评估,到目前为止。另一种COX-2药物罗非昔布(rofecoxib)即将释放。它更强的COX-2选择性引发了新的问题。一些作者在风湿性滑膜炎中检测到COX-1活性如何?另一方面,在特殊情况下,胃、肾和小血管等器官的体内平衡似乎也部分受到COX-2机制的控制。随着COX-2药物临床经验的积累,这些问题将很快得到解答。
{"title":"Novel nonsteroidal anti-inflammatory drugs.","authors":"Y Boutsen,&nbsp;W Esselinckx","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The authors first briefly review how the concept of COX-2 selectivity was brought to light, then tested against the known gastrotoxicity ranking of currently used NSAIDs, from the old classics to the most recent. One truly selective COX-2 agent--celecoxib--is now being marketed in an ever increasing number of countries. So far it seems to keep its main promises, i.e. high--albeit not total--safety regarding gastrointestinal adverse effects, and undisturbed platelet function. Association with warfarin drugs seems to raise no problems, but one should still be wary of possible renal side-effects. Efficacy, at least as assessed in osteoarthritis and rheumatoid patients, appears satisfactory. However, treatment of intense inflammatory crises, such as gout or ankylosing spondylitis, has not been assessed, as yet. Another COX-2 agent--rofecoxib--is on the brink of being released. Its even more potent COX-2 selectivity raises new issues. What about some COX-1 activity that several authors detected in rheumatic synovitis? On the other hand, in particular circumstances, organs such as the stomach, the kidney and small blood vessels, seem to have their homeostasis partly controlled by COX-2 mechanisms also. These questions should be answered soon, whilst clinical experience with the COX-2 agent builds up.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"421-4"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffuse liver angiosarcoma and cerebral cavernous angiomas in a young patient. 弥漫性肝血管肉瘤及脑海绵状血管瘤1例。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
J Janssens, B Boland, A P Draguet, B E Van Beers, C Godfraind, J Rahier, J Lerut, A Geubel

A case of a thirty-nine year old woman with cerebral cavernous angiomas who developed anaemia and thrombocytopenia secondary to diffuse liver angiosarcoma is reported. This unique association of liver angiosarcoma and cerebral cavernous angiomas may suggest that this tumour may potentially develop from benign vascular lesions. Hematologic abnormalities in angiosarcomas are moreover reviewed based on recent literature search.

一例39岁女性脑海绵状血管瘤并发贫血和血小板减少继发于弥漫性肝血管肉瘤。肝血管肉瘤和脑海绵状血管瘤的这种独特联系可能表明这种肿瘤可能是由良性血管病变发展而来的。此外,根据最近的文献检索,对血管肉瘤的血液学异常进行了综述。
{"title":"Diffuse liver angiosarcoma and cerebral cavernous angiomas in a young patient.","authors":"J Janssens,&nbsp;B Boland,&nbsp;A P Draguet,&nbsp;B E Van Beers,&nbsp;C Godfraind,&nbsp;J Rahier,&nbsp;J Lerut,&nbsp;A Geubel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A case of a thirty-nine year old woman with cerebral cavernous angiomas who developed anaemia and thrombocytopenia secondary to diffuse liver angiosarcoma is reported. This unique association of liver angiosarcoma and cerebral cavernous angiomas may suggest that this tumour may potentially develop from benign vascular lesions. Hematologic abnormalities in angiosarcomas are moreover reviewed based on recent literature search.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"446-9"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and treatment of hepatocellular carcinoma. 肝细胞癌的诊断与治疗。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
Y Suarez, M Sala, J M Llovet, J Bruix

Several advances have been produced in the diagnosis and treatment of patients with hepatocellular carcinoma. It is possible to diagnose the neoplasm at an early stage when radical treatment options may be applied. The criteria to apply them successfully have been refined and the expected outcome has been improved, but we still lack a useful treatment for the vast majority of patients who are still diagnosed at an advanced stage. Efforts have to be done during the next years to develop such an option (perhaps based on gene manipulation) and until then the management of this tumour will still constitute a challenge for physicians taking care of patients with this neoplasm.

在肝细胞癌的诊断和治疗方面取得了一些进展。在早期阶段进行根治性治疗是有可能诊断出肿瘤的。成功应用它们的标准已经得到了改进,预期的结果也得到了改善,但对于绝大多数仍被诊断为晚期的患者,我们仍然缺乏有效的治疗方法。在接下来的几年里,必须努力开发这样的选择(可能基于基因操作),在此之前,这种肿瘤的管理对照顾这种肿瘤患者的医生来说仍然是一个挑战。
{"title":"Diagnosis and treatment of hepatocellular carcinoma.","authors":"Y Suarez,&nbsp;M Sala,&nbsp;J M Llovet,&nbsp;J Bruix","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several advances have been produced in the diagnosis and treatment of patients with hepatocellular carcinoma. It is possible to diagnose the neoplasm at an early stage when radical treatment options may be applied. The criteria to apply them successfully have been refined and the expected outcome has been improved, but we still lack a useful treatment for the vast majority of patients who are still diagnosed at an advanced stage. Efforts have to be done during the next years to develop such an option (perhaps based on gene manipulation) and until then the management of this tumour will still constitute a challenge for physicians taking care of patients with this neoplasm.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"410-4"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodality treatment of cancer of the digestive tube: the standard in 1998. Colorectal cancer. 消化管癌的综合治疗:1998年标准。结直肠癌。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
L Påhlman
{"title":"Multimodality treatment of cancer of the digestive tube: the standard in 1998. Colorectal cancer.","authors":"L Påhlman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"432-6"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haemochromatosis and HFE gene. 血色病与HFE基因。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
R Moirand, Y Deugnier, P Brissot

The discovery of the HFE gene has improved classification and diagnosis of iron overload. Most patients with a phenotypic diagnosis of haemochromatosis are homozygote for the C282Y mutation. Among those with other genotypes, only compound heterozygotes, who present the C282Y mutation on one chromosome and the H63D on the other, may present with haemochromatosis, but with a low penetrance and a mild expression. Other patients usually present with another cause of iron overload, such as insulin resistance, alcoholic liver disease or liver cirrhosis. The practical management of haemochromatosis has been greatly modified, since liver biopsy is no more necessary for diagnosis in C282Y homozygotes, and is only needed for exclusion of cirrhosis. Family screening has also greatly benefited from genotyping.

HFE基因的发现改善了铁超载的分类和诊断。大多数血色病的表型诊断是纯合子的C282Y突变。在其他基因型中,只有复合杂合子(一条染色体为C282Y突变,另一条染色体为H63D突变)可能出现血色素沉着病,但外显率低,表达轻微。其他患者通常表现为铁超载的其他原因,如胰岛素抵抗、酒精性肝病或肝硬化。血色素病的实际治疗已经有了很大的改进,因为C282Y纯合子的诊断不再需要肝活检,只需要排除肝硬化。基因分型也极大地促进了家庭筛查。
{"title":"Haemochromatosis and HFE gene.","authors":"R Moirand,&nbsp;Y Deugnier,&nbsp;P Brissot","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The discovery of the HFE gene has improved classification and diagnosis of iron overload. Most patients with a phenotypic diagnosis of haemochromatosis are homozygote for the C282Y mutation. Among those with other genotypes, only compound heterozygotes, who present the C282Y mutation on one chromosome and the H63D on the other, may present with haemochromatosis, but with a low penetrance and a mild expression. Other patients usually present with another cause of iron overload, such as insulin resistance, alcoholic liver disease or liver cirrhosis. The practical management of haemochromatosis has been greatly modified, since liver biopsy is no more necessary for diagnosis in C282Y homozygotes, and is only needed for exclusion of cirrhosis. Family screening has also greatly benefited from genotyping.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"403-9"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histopathological assessment of the prophylactic effect of gingko-biloba extract on intestinal ischemia-reperfusion injury. 银杏叶提取物对肠缺血再灌注损伤预防作用的组织病理学评价。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
A Onen, E Deveci, S S Inalöz, B Isik, M Kilinc

In this experimental study, the prophylactic effects of Gingko-Biloba Extract (GBE) were examined after experimental ischemia on intestinal wall damage. 50 Wistar-Albino rats (2.5 month old) were gathered and separated into 5 groups (n:10). Group 1 was subjected to a laparotomy (sham-operated group) whereas all other experimental groups were subjected to an occlusion of their superior mesenteric arteries for 30 minutes and a period of 20 minutes reperfusion following occlusion. Group 2 was not given any prophylactic agent during the experiment (untreated control group). GBE was administered in a dosage of 50 mg/kg (i.v.) as a prophylactic agent to Group 3 one hour prior to laparotomy whereas Group 4 was given GBE at 50 mg/kg (i.v.) just before ischemia. Group 5 was given GBE in the same dosage just before reperfusion. Immediately after reperfusion, a biopsy was taken from the ileum (10 cm proximity to ileocaecal valve) for histopathological assessment. A significant prophylactic effect of GBE was observed in Group 5 in which GBE was administered just before reperfusion.

本实验研究了银杏叶提取物(GBE)对实验性缺血后肠壁损伤的预防作用。取2.5月龄Wistar-Albino大鼠50只,随机分为5组(n:10)。实验组1开腹手术(假手术组),其余实验组均闭塞肠系膜上动脉30分钟,闭塞后再灌注20分钟。2组在实验期间不给予任何预防药物(未给予治疗的对照组)。实验组3在剖腹手术前1小时以50mg /kg(静脉注射)剂量给予GBE,实验组4在缺血前以50mg /kg(静脉注射)剂量给予GBE。第5组在再灌注前给予相同剂量的GBE。再灌注后立即从回肠(距回盲瓣10cm处)取活检进行组织病理学评估。第5组在再灌注前给予GBE,观察到GBE有显著的预防作用。
{"title":"Histopathological assessment of the prophylactic effect of gingko-biloba extract on intestinal ischemia-reperfusion injury.","authors":"A Onen,&nbsp;E Deveci,&nbsp;S S Inalöz,&nbsp;B Isik,&nbsp;M Kilinc","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this experimental study, the prophylactic effects of Gingko-Biloba Extract (GBE) were examined after experimental ischemia on intestinal wall damage. 50 Wistar-Albino rats (2.5 month old) were gathered and separated into 5 groups (n:10). Group 1 was subjected to a laparotomy (sham-operated group) whereas all other experimental groups were subjected to an occlusion of their superior mesenteric arteries for 30 minutes and a period of 20 minutes reperfusion following occlusion. Group 2 was not given any prophylactic agent during the experiment (untreated control group). GBE was administered in a dosage of 50 mg/kg (i.v.) as a prophylactic agent to Group 3 one hour prior to laparotomy whereas Group 4 was given GBE at 50 mg/kg (i.v.) just before ischemia. Group 5 was given GBE in the same dosage just before reperfusion. Immediately after reperfusion, a biopsy was taken from the ileum (10 cm proximity to ileocaecal valve) for histopathological assessment. A significant prophylactic effect of GBE was observed in Group 5 in which GBE was administered just before reperfusion.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"386-9"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of the E-cadherin/catenin complex in gastrointestinal cancer. e -钙粘蛋白/连环蛋白复合物在胃肠道肿瘤中的作用。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
P Debruyne, S Vermeulen, M Mareel

Cancer is a genetic disease. The unstable genome of cancer cells causes tumour progression through multiple alterations in suppressor and promoter genes, leading to loss of homeostatic and gain of oncogenic functions. Invasion is the critical step in the acquisition of malignancy. It implicates a continuous molecular conversation of the cancer cells with other cells and with the extracellular matrix in which adhesion molecules are crucial. One of these, E-cadherin, is discussed in the present review. E-cadherin is a transmembrane glycoprotein that forms a complex with cytoplasmic proteins, termed catenins because they link E-cadherin to the actin cytoskeleton. E-cadherin/catenin-mediated intercellular adhesion and communication is mainly homophylic homotypic. There is compelling evidence from experiments in vitro as well as in vivo to accept that the E-cadherin/catenin complex acts as an invasion suppressor. The mechanism of this action is not only through cell-cell adhesion but also through transduction of signals to the cell's motility system. In the replication error positive human colon cancer cell line HCT-8, the alpha E-catenin gene CTNNA1 is an invasion suppressor gene. Here, the transition from the non-invasive to the invasive state was prevented by introduction into the unstable non-invasive cells of either an extra CTNNA1 or a wild type hMSH6 mismatch repair gene. beta-catenin also participates at a complex which comprises the adenomatous polyposis cancer protein APC. In colorectal cancer, mutation of either APC or beta-catenin is oncogenic. Downregulation of the E-cadherin/catenin complex may occur in several ways amongst which are gene mutations, methylation of 5'CpG dinucleotides within the promotor region of E-cadherin, tyrosine phosphorylation of beta-catenin, cell surface expression of proteoglycans sterically hindering E-cadherin and proteolytic release of fragments from the extracellular part of E-cadherin. Upregulation of the E-cadherin/catenin complex has been realized with a series of agents, some of which can be used therapeutically. In most human gastrointestinal cancers the E-cadherin/catenin or related complexes are disturbed and this underscores their pivotal role in the progression of these tumours. Mutations of the E-cadherin gene, including germline mutations, occur in diffuse gastric carcinoma, CpG methylation around the promotor region of E-cadherin in hepatocellular carcinomas and mutations of the APC tumour suppressor gene or in the beta-catenin oncogene in most colorectal cancers. The literature agrees about the disturbance of immunohistochemical patterns of E-cadherin and catenin expression in gastrointestinal cancers. Conflicting opinions do, however, exist about the prognostic value of such immunohistochemical aberrations. We doubt that immunohistochemistry of E-cadherin or catenins add prognostic value to the already used histological grading systems. In our opinion the major benefit from understanding

癌症是一种遗传性疾病。癌细胞不稳定的基因组通过抑制基因和启动基因的多重改变导致肿瘤进展,导致稳态功能的丧失和致癌功能的获得。侵袭是恶性肿瘤形成的关键步骤。它暗示癌细胞与其他细胞和与细胞外基质的连续分子对话,其中粘附分子是至关重要的。其中之一,e -钙粘蛋白,是讨论在本综述。e -钙粘蛋白是一种跨膜糖蛋白,与细胞质蛋白形成复合物,称为连环蛋白,因为它们将e -钙粘蛋白连接到肌动蛋白细胞骨架上。E-cadherin/catenin介导的细胞间粘附和通讯主要是同型的。体外和体内实验都有令人信服的证据表明,E-cadherin/catenin复合物具有侵袭抑制作用。这种作用的机制不仅是通过细胞间的粘附,还通过信号转导到细胞的运动系统。在复制错误阳性的人结肠癌细胞系HCT-8中,α e -连环蛋白基因CTNNA1是一种侵袭抑制基因。在这里,通过在不稳定的非侵入性细胞中引入额外的CTNNA1或野生型hMSH6错配修复基因,阻止了从非侵入状态到侵入状态的转变。-连环蛋白也参与一个包含腺瘤性息肉癌蛋白APC的复合体。在结直肠癌中,APC或β -连环蛋白的突变都是致癌的。E-cadherin/catenin复合物的下调可能以多种方式发生,其中包括基因突变,E-cadherin启动子区域内5'CpG二核苷酸的甲基化,β -catenin的酪氨酸磷酸化,细胞表面蛋白聚糖的表达立体阻碍E-cadherin,以及E-cadherin细胞外部分蛋白水解释放片段。E-cadherin/catenin复合物的上调已通过一系列药物实现,其中一些可用于治疗。在大多数人类胃肠道癌症中,e -钙粘蛋白/连环蛋白或相关复合物受到干扰,这强调了它们在这些肿瘤进展中的关键作用。E-cadherin基因的突变,包括种系突变,发生在弥漫性胃癌中,发生在肝细胞癌中,发生在E-cadherin启动子区域周围的CpG甲基化,发生在大多数结直肠癌中,发生在APC肿瘤抑制基因或β -catenin癌基因的突变。文献一致认为E-cadherin和catenin在胃肠道肿瘤中表达的免疫组化模式受到干扰。然而,关于这种免疫组织化学异常的预后价值,存在着相互矛盾的观点。我们怀疑e -钙粘蛋白或连环蛋白的免疫组化对已经使用的组织学分级系统增加了预后价值。在我们看来,了解E-cadherin/catenin介导的侵袭途径的主要好处将是开发新的抗侵袭治疗策略。
{"title":"The role of the E-cadherin/catenin complex in gastrointestinal cancer.","authors":"P Debruyne,&nbsp;S Vermeulen,&nbsp;M Mareel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer is a genetic disease. The unstable genome of cancer cells causes tumour progression through multiple alterations in suppressor and promoter genes, leading to loss of homeostatic and gain of oncogenic functions. Invasion is the critical step in the acquisition of malignancy. It implicates a continuous molecular conversation of the cancer cells with other cells and with the extracellular matrix in which adhesion molecules are crucial. One of these, E-cadherin, is discussed in the present review. E-cadherin is a transmembrane glycoprotein that forms a complex with cytoplasmic proteins, termed catenins because they link E-cadherin to the actin cytoskeleton. E-cadherin/catenin-mediated intercellular adhesion and communication is mainly homophylic homotypic. There is compelling evidence from experiments in vitro as well as in vivo to accept that the E-cadherin/catenin complex acts as an invasion suppressor. The mechanism of this action is not only through cell-cell adhesion but also through transduction of signals to the cell's motility system. In the replication error positive human colon cancer cell line HCT-8, the alpha E-catenin gene CTNNA1 is an invasion suppressor gene. Here, the transition from the non-invasive to the invasive state was prevented by introduction into the unstable non-invasive cells of either an extra CTNNA1 or a wild type hMSH6 mismatch repair gene. beta-catenin also participates at a complex which comprises the adenomatous polyposis cancer protein APC. In colorectal cancer, mutation of either APC or beta-catenin is oncogenic. Downregulation of the E-cadherin/catenin complex may occur in several ways amongst which are gene mutations, methylation of 5'CpG dinucleotides within the promotor region of E-cadherin, tyrosine phosphorylation of beta-catenin, cell surface expression of proteoglycans sterically hindering E-cadherin and proteolytic release of fragments from the extracellular part of E-cadherin. Upregulation of the E-cadherin/catenin complex has been realized with a series of agents, some of which can be used therapeutically. In most human gastrointestinal cancers the E-cadherin/catenin or related complexes are disturbed and this underscores their pivotal role in the progression of these tumours. Mutations of the E-cadherin gene, including germline mutations, occur in diffuse gastric carcinoma, CpG methylation around the promotor region of E-cadherin in hepatocellular carcinomas and mutations of the APC tumour suppressor gene or in the beta-catenin oncogene in most colorectal cancers. The literature agrees about the disturbance of immunohistochemical patterns of E-cadherin and catenin expression in gastrointestinal cancers. Conflicting opinions do, however, exist about the prognostic value of such immunohistochemical aberrations. We doubt that immunohistochemistry of E-cadherin or catenins add prognostic value to the already used histological grading systems. In our opinion the major benefit from understanding ","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"393-402"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare cause of biliary pain in Belgium. 比利时胆道疼痛的罕见病因。
IF 1.5 4区 医学 Q2 Medicine Pub Date : 1999-10-01
N Botembe, G Cabrera-Alvarez, O Le Moine, M Cremer

Ascaris lumbricoides is the most frequent human helminthic parasite. Usually human ascariasis is poorly symptomatic but complications can arise due to worm migration. Erratic worm migration into the biliary tree is a rare but threatening condition regarding the associated complications: cholecystitis, pancreatitis, obstruction of bile ducts, liver abcesses and recurrent pyogenic cholangitis. We describe a case of a young belgian women suffering from recurrent biliary colics over a period of eight months with repeated normal ultrasound findings. ERCP proved being the only effective diagnostic procedure for a living biliary worm, which was successfully removed with a balloon catheter.

类蚓蛔虫是最常见的人类寄生虫。通常人类蛔虫病症状较差,但由于蠕虫的迁移可引起并发症。不稳定的蠕虫向胆道树的迁移是一种罕见但具有威胁性的疾病,其相关并发症包括胆囊炎、胰腺炎、胆管梗阻、肝脓肿和复发性化脓性胆管炎。我们描述了一个年轻的比利时妇女患复发性胆道绞痛超过八个月的反复正常超声结果的情况下。ERCP被证明是对活的胆道蠕虫唯一有效的诊断程序,它被成功地用球囊导管切除。
{"title":"A rare cause of biliary pain in Belgium.","authors":"N Botembe,&nbsp;G Cabrera-Alvarez,&nbsp;O Le Moine,&nbsp;M Cremer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ascaris lumbricoides is the most frequent human helminthic parasite. Usually human ascariasis is poorly symptomatic but complications can arise due to worm migration. Erratic worm migration into the biliary tree is a rare but threatening condition regarding the associated complications: cholecystitis, pancreatitis, obstruction of bile ducts, liver abcesses and recurrent pyogenic cholangitis. We describe a case of a young belgian women suffering from recurrent biliary colics over a period of eight months with repeated normal ultrasound findings. ERCP proved being the only effective diagnostic procedure for a living biliary worm, which was successfully removed with a balloon catheter.</p>","PeriodicalId":50942,"journal":{"name":"Acta Gastro-Enterologica Belgica","volume":"62 4","pages":"443-5"},"PeriodicalIF":1.5,"publicationDate":"1999-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21545801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Gastro-Enterologica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1